Podcast 10 May 2024
Cytokinetics’ cardiovascular pipeline beats strong
Discover Cytokinetics’ groundbreaking cardiovascular treatments, including heart drug aficamten, in our latest podcast with CEO Robert Blum.
Cardiovascular disease
- Latest Posts
In Depth 8 May 2024
New treatment for pulmonary hypertension: what biotech holds in store?
While it has been about managing pulmonary hypertension’s symptoms for a long time, new treatments are adressing the root of the disease.
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
Podcast 10 Nov 2023
How biotech can mend a broken heart
CellProthera has been working to do the impossible – mend broken hearts. The biotech company’s ProtheraCytes cell therapy regenerates damaged tissue following a heart attack, thus restoring cardiac function. In this podcast, we investigate regenerative therapy with CellProthera’s CEO, Matthieu de Kalbermatten. While regenerative cell therapy is dependent on the patient’s own cells, and reliant […]
News and Trends 17 Jul 2023
Lilly boosts obesity portfolio with Versanis Bio acquisition
Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]
Best in Biotech 8 Jun 2023
Six companies that have made their name in the cardiovascular space
Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with statistics from 2019 stating that an estimated 17.9 million people died from some type of cardiovascular disease, making up 32% […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 19 May 2023
Can cardiovascular diseases be cured? The future of heart treatment
Cardiovascular diseases, characterized as a group of disorders of the heart and blood vessels, are the leading cause of death worldwide. In fact, in the U.S. alone, it is thought that one person dies every 33 seconds from cardiovascular disease. Although clearly a huge health problem throughout the world, developing cures for cardiovascular diseases is […]
News and Trends 26 Apr 2023
LincRNA discovery could lead to targeted treatments
Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up sections of our genome called topologically associating domains, or TADs. LincRNAs derived from TADs appear to act as markers indicating the specific kind of tissue they are within. When something […]
News and Trends 11 Apr 2023
Calida Therapeutics launches to tackle thrombo-inflammatory disorders
Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […]
News and Trends 31 Mar 2023
Destiny Pharma gel reduces nasal staph in surgery patients
Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections. The data was published in the journal Infection Control & Hospital Epidemiology. The paper was […]
News and Trends 10 Feb 2023
Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study
Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […]
News and Trends 2 Feb 2023
Possible drug targets from Korean atherosclerosis research
Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […]
ADVERTISEMENT
